Onychiol B attenuates lipopolysaccharide-induced inflammation via MAPK/NF-κB pathways and acute lung injury in vivo

Xiaoxiao Pei; Zeyi Zhang; Nina Wang; Guozheng Huang; Xiaoran Min; Yanzi Yang; Jianguo Cao

doi:10.1016/j.bioorg.2023.106351

Onychiol B attenuates lipopolysaccharide-induced inflammation via MAPK/NF-κB pathways and acute lung injury in vivo

Bioorg Chem. 2023 Mar:132:106351. doi: 10.1016/j.bioorg.2023.106351. Epub 2023 Jan 11.

Authors

Xiaoxiao Pei¹, Zeyi Zhang², Nina Wang³, Guozheng Huang⁴, Xiaoran Min¹, Yanzi Yang⁵, Jianguo Cao⁶

Affiliations

¹ College of Life Sciences, Shanghai Normal University, Shanghai 200234, China.
² School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
³ College of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, China.
⁴ College of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, China. Electronic address: guozheng.huang@ahut.edu.cn.
⁵ School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China. Electronic address: yangyanzi@zcmu.edu.cn.
⁶ College of Life Sciences, Shanghai Normal University, Shanghai 200234, China. Electronic address: cao101@shnu.edu.cn.

PMID: 36642022
DOI: 10.1016/j.bioorg.2023.106351

Abstract

Acute lung injury (ALI) is a devastating respiratory disorder characterized by rapid alveolar injury, uncontrolled inflammatory response, etc. Onychiol B is a cyathane diterpene originally isolated from fern plants. In this study, onychiol B can inhibit the production and secretion of pro-inflammatory cytokines such as NO, iNOS, IL-6 and TNF-α in LPS-stimulated RAW264.7 cells by restraining the NF-κB and the p38 MAPK pathway. In addition, it prevents the production of ROS and reduces the loss of mitochondrial membrane potential in LPS-stimulated RAW264.7 cells. Furthermore, in the acute lung injury mouse model induced by LPS injected into the trachea, onychiol B alleviates pulmonary edema, reverses inflammatory mediator TNF-α, IL-6, and IL-β secretion in lung. In general, our data show that significant anti-ALI effects of onychiol B would render it a potential candidate for the treatment of inflammatory diseases.

Keywords: Acute lung injury; Inflammation; Onychiol B; ROS.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Lung Injury* / chemically induced
Acute Lung Injury* / drug therapy
Animals
Cytokines / metabolism
Inflammation / chemically induced
Inflammation / drug therapy
Interleukin-6
Lipopolysaccharides / adverse effects
Mice
NF-kappa B* / metabolism
RAW 264.7 Cells
Tumor Necrosis Factor-alpha / metabolism

Substances

NF-kappa B
Lipopolysaccharides
Tumor Necrosis Factor-alpha
Interleukin-6
Cytokines